Perspective advancements in understanding and managing dry eye disease

International Journal of Pharmaceutical Sciences Review and Research

Volumn 7, Issue 1, 2011, Pages 100-107

  Kaushik, Dhirender ^a   Syan, Navneet ^b   Handa, Vandana ^c   Mathur, Pooja ^b   Kaushik, Pawan ^a   Rani, Shalu ^a  

^a KURUKSHETRA UNIVERSITY   (India)

^b Ganpati Institute of Pharmacy   (India)

^c KRISHNA INSTITUTE OF ENGINEERING AND TECHNOLOGY   (India)

Author keywords

Dry eye syndrome; Keratoconjunctivitis sicca (KCS); Tear film

Indexed keywords

AMBROXOL; ANDROGEN; ARTIFICIAL TEAR; BOTULINUM TOXIN; BROMHEXINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CYCLOSPORIN A; DRUG PRESERVATIVE; ELEDOSIN; ESTROGEN; ESTROGEN RECEPTOR; EYE DROPS; HYALURONIC ACID; HYDROXYPROPYLCELLULOSE; LIPID; LUBRICATING AGENT; MUCIN; OMEGA 3 FATTY ACID; PILOCARPINE; RETINOL PALMITATE; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS SERUM; BLEPHAROSPASM; DIAGNOSTIC TEST; DRUG ERUPTION; DRUG FORMULATION; DRUG MECHANISM; DRY EYE; EVAPORATION; EXTRAOCULAR MUSCLE; EYE; EYE CARE; EYELID REFLEX; FACE CLOTH; HIGH RISK POPULATION; HOUSEHOLD; HUMAN; HUMIDITY; INFLAMMATION; KERATOCONJUNCTIVITIS SICCA; LACRIMAL FLUID; LACRIMATION; NAUSEA; NONHUMAN; OCULAR SURFACE; SERUM; SIDE EFFECT; SJOEGREN SYNDROME; SWEATING; SYMPTOM; TEAR FILM; TEAR FILM COMPOSITION; VISCOSITY; VISUAL ACUITY; WARM TAP WATER COMPRESS; WARMING; XEROPHTHALMIA;

EID: 80052653464     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea, 17, 1998, 584-589.
2. Bron AJ, Sci FM, Tiffany JM. The contribution of meibomian disease to dry eye. Ocul Surf., 2, 2004, 149-65.
3. Gupta P. D, Pushkala K. Human Syndromes: A complete guide. Oxford and IBH Publishing Co. New Delhi, 2005.
4. Holly FJ, Lemp MA. Tear physiology and dry eyes. Surv Ophthalmol., 22, 1977, 69.
5. Mishima S. Some physiological aspects of the precorneal tear film. Arch Ophthalmol., 73, 1965, 233.
6. Sullivam DA, Wickham LA, Krenzer KL, Rocha EM, Toda I. Aqueous tear deficiency in Sjogren's syndrome. Possible cause and potential treatment. In Pleyer U, Nart mann C, Sterry W (eds): Oculodermal diseases immunology of Bullous Oculo-Muco-Cutaneous Disorders, Buren. The Netherlands, Aeolus Press, 1997, 95-152.
7. Lemp MA, Hamill JR. Factors affecting tear film breakup in normal eyes. Arch Ophthalmol., 89, 1973, 103.
8. Schein OD, Tielsch JM, Munoz B, Bandeen-Roche K, West Sl. Relation between signs and symptoms of dry eye in the elderly: a population-based perspective. Ophthalmol., 104, 1997, 1395-1401.
9. Johnson ME, Murphy PJ. Changes in the tear film and ocular surface from dry eye syndrome. Prog Retin Eye Res., 23, 2004, 449-474.
10. Pflugfelder SC, Solomon A, Dursun D, Li DQ. Dry eye and delayed tear clearance: a call to arms. Adv Exp Med Biol., 506, 2002, 739-743.
11. Narayanan S, Miller WL, McDermott AM. Conjunctival cytokine expression in symptomatic moderate dry eye subjects. Invest Ophthalmol Vis Sci., 47, 2006, 2445-2450.
12. Song XJ, Li DQ, Farley W, Luo LH, Heuckeroth RO, Milbrandt J. Neurturin-deficient mice develop dry eye and keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci., 44, 2003, 4223-4229.
13. American Academy of Ophthalmology. Preferred practice pattern: Dry eye syndrome. San Francisco: AAO, 2003.
14. Breil P, Frisch L, Dick HB. Diagnosis and therapy of LASIK induced neurotrophic epitheliopathy. Ophthalmol., 99, 2002, 53-57.
15. Moss SE, Klein R, Klein BE. Prevalence and risk factors for dry eye syndrome. Arch Ophthalmol., 118, 2000, 1264-1268.
16. Nelson JD, Helms H, Fiscella R, Southwell Y, Hirsch JD. A new look at dry eye disease and its treatment. Adv Ther., 17, 2000, 84-93.
17. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a 25-year review. Cornea, 19, 2000a, 644-649.
18. Lemp MA. Basic principles and classification of dry eye disorders. In Lemp MA, Marquardt R (eds). Springer- Verlag, Berlin, 1992, 101-131.
19. Hass EB. The pathogenesis of keratoconjunctivitis sicca. Ophthalmol., 147, 1964, 1.
20. Sjogrenh. Keratoconjunctivites sicca. In Ridly F, Sorsby A (eds). Modern & trends in ophthalmology. London, Butterworth & Co. Ltd., 1940, 403-413.
21. rded. Boston Little Brown, 1994, 439.
22. Tiffany JM. Physiological functions of the meibomian glands. Prog Ret Eye Res., 14, 1995, 47.
23. Pflugfelder SC, Liu Z, Monroy D, Li DQ, Carvajal ME, Price-Schiavi SA, Idris N, Perez A. Detection of sialomucin complex (MUC4) in human ocular surface epithelium and tear fluid. Invest Ophthalmol Vis Sci., 41, 2000b, 1316-1326.
24. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf., 1, 2003, 107-126.
25. Bron AJ, Tiffany JM, Gouveia SM, Yokoi N, Voon LW. Functional aspects of the tear film lipid layer. Exp Eye Res., 78, 2004, 347-360.
26. McCulley JP, Shine W. A compositional based model for the tear film lipid layer. Trans Am Ophthalmol Soc., 95, 1997, 79-93.
27. Goto E, Endo K, Suzuki A, Fujikura Y, Matsumoto Y, Tsubota K. Tear evaporation dynamics in normal subjects and subjects with obstructive meibomian gland dysfunction. Invest Ophthalmol Vis Sci., 44, 2003, 533-599.
28. Mathers WD, Lane JA, Meibomian gland lipid, evaporation, and tear film stability, In Sullivan DA (eds). Lacrimal Gland, Tear Film, and Dry Eye Syndromes 2. New York, NY, Plenum Press, 1998, 349-360.
29. Bron AJ, Sci FM, Tiffany JM, The contribution of meibomian disease to dry eye. Ocul Surf., 2, 2004, 149-165.
30. Bron AJ, Tiffany JM, Gouveia SM, Yokoi N, Voon LW. Functional aspects of the tear film lipid layer. Exp Eye Res., 78, 2004, 347-360.
31. Lemp MA, Foulks GN, Devgan U, et al. The therapeutic role of lipids: managing ocular surface disease. Refract Eyecare for Ophthamol., 9, 2005, 3-15.
32. Marfurt CF. Nervous control of cornea. In Burnstock G, Sillito A (eds) Innervation of the Eye, London, Gordon & Breach Science, 1997.
33. Ophthalmology Times. Nutritional supplementation stimulates tear production, 15th May 2003, 28.
34. Mc Event WK. Secretion of tears and blimking. In Davson H (eds): The Eye, Vol. 3, New York, Academic, 1962, 271-305.
35. Doane MG. Blinking and the mechanics of the lacrimal drainage system, Ophthalmol., 88, 1981, 844-851.
36. Carney LG, Hill RM. The nature of normal blinking patter. Acta Ophthalmol., 60, 1982, 427-423.
37. Dartt DA. Physiology of tear production. In lemp MA, Marquardt R, (eds). The Dry Eye Berlin, Springer-Verlog, 1992, 65-69.
38. Abdel-Khalek LMR, Williamson J, Lee WR. Morphological changes in the human conjunctival epithelium in keratoconjunctivitis sicca. Br J Ophthalmol. 1978, 62, 800-806.
39. Lemp MA. Report of the National eye Institute/Industry. A workshop on clinical trials in dry eyes. CLAOJ, 21, 1995, 221-232.
40. Rolands M. Refojo MF, Kenyon KR. Ineseased tear evaporation in eyes with keratoconjunctivitis sicca. Arch Ophthaloml., 101, 1983, 557-558.
41. Carolyn G. The relationship between habitual patients reported symptoms and clinical signs among patients with dry eye of varying severity. Investigative Ophthalmology and Visual Science, 44, 2003, 4753-4761.
42. Van Bijsterveld OP. Diagnostic tests in the sicca syndrome. Arch Ophthalmol., 82, 1985, 10.
43. Farris RL, Gilbard JP, Stuchell RN, Mandel ID. Diagnostic tests in keratoconjunctivitis sicca. CLAOJ, 9, 1983, 23-28.
44. Heigle TJ, Pflugfelder SC. Aqueous tear production in patients with neurotrophic keratitis. Cornea, 15, 1996, 135-138.
45. Nanavaty MA, Vasavada AR, Gupta PD. Dry eye syndrome. Asian J Exp Sci., 20, 2006, 63-80.
46. Mircheff AK. Understanding the cause of lacrimal insufficiency: Implication for treatment and prevention of dry eye syndrome. In research to Present Blindness Science Writers Seminar, New York, 1993, 51-54.
47. Schiffman RM, Christianson MD, Jacoksen G, Hirsch JD, Reis BL. Reliability and validity of the ocular surface disease index. Arch Ophthalmol., 118, 2002, 615-621.
48. Maurice DM. The tonicity of an eye drop and its dilution by tears. Exp. Eye Res., 11, 1971, 30-33.
49. Pfister RR, Burnstein N. The effects of ophthalmic drugs, electron microscope study. Invest Ophthalmol., 15, 1976, 246-259.
50. Burnjstein NL. Corneal cytotoxicity of topical applied drug, vehicles, and preservatives. Surv Ophthalmol., 25, 1980, 15-29.
51. Dohsman CH. Punctal occlusion in keratoconjunctivitis sicca. Ophthalmol., 85, 1978, 1277-1281.
52. Tuberville AW, Frederick WR, Wood TO. Punctal occlusion in tear deficiency syndromes. Ophthalmology, 89, 1982, 1170-1172.
53. Gilbord JP, Kenyon KR. Tear diluents in the treatment of keratoconjunctivitis sicca. Ophthalmology, 92, 1985, 646-650.
54. Kokke K, Morris J, Lawrenson J. Oral omega-6 essential fatty acids treatment in contact lense associated dry eye. CLAE, 31, 2008, 141-146.
55. Turner K, Pflugfelder SC, Ji Z, Fever WJ, Stern M, Reis BL. Interleukin-6 levels in the conjunctival to epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea, 19, 2000, 492-496.
56. Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patient's lymphocytes. Arch Ophthalmol., 118, 2000, 1489-1496.
57. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease: CsA Phase 3 Study Group. Ophthalmology, 107, 2000, 631-639.
58. Small DS, Acheampong A, Reis B, Sterm K, Stewart W, Berdy G, Epstein R, Foerster R, Forstot L, Tan-Liu DDS. Blood concentration of cyclosporine A during long term treatment with cyclosporine A ophthalmic emulsions in patient with moderate to severe dry eye disease. J Ocular Pharmacol Ther., 18, 2002, 411-418.
59. Kim EC, Choi JS, Joo CK. A comparison of vitamin A and cyclosporine A 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol., 147, 2009, 206-213.
60. Zeilgs MA, Gordon K. Dehydroepiandrorterone therapy for the treatment of dry eye disorders. Int Patient Application WO. 94/04155 March 1994.
61. Shimmura S, Ono M, Shinozaki K, Toda I, Takamura E, Mashima Y, Tsubota K. Sodium hyaluronate eye drops in the treatment of dry eyes. Br J Ophthalmol., 79, 1995, 1007-1011.
62. McDonald CC, Kaye SB, Figueiredo FC, Macintosh G, Lockett C. A randomised crossover, multicentre study to compare the performance of 0.1% (w/v) sodium hyaluronate with 1.4% (w/v) polyvinyl alcohol in the alleviation of symptoms associated with dry eye syndrome. Eye, 16, 2002, 601-607.
63. Brignole F, Pisella PJ, Dupas B, Baeyens V, Baudouin Cl. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefes Arch Clin Exp Ophthalmol., 243, 2005, 531-538.
64. Johnson ME, Murphy PJ, Boulton M. Carbomer and sodium hyaluronate eyedrops for moderate dry eye treatment. Optom Vis Sci., 85, 2008, 750-757.
65. Prabhasawat P, Tesavibul N, Kasetsuwan N. Performance profile of sodium hyaluronate in patients with lipid tear deficiency: randomised, double-blind, controlled, exploratory study. Br J Ophthalmol., 91, 2007, 47-50.
66. Aragona P, Di Stefano G, Ferreri F, Spinella R, Stilo A. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjogren's syndrome patients. Br J Ophthalmol., 86, 2002, 879-84.
67. Choy EPY, Cho P, Benzie IFF, Choy CKM. Investigation of corneal effect of different types of artificial tears in a simulated dry eye condition using a novel porcine dry eye model (pDEM). Cornea, 25, 2006, 1200-1204.
68. Dry eye syndrome, managed care, published by MediMedia USA Inc., at 780 Township Line Road, Yardley, PA 19067,12, 2003, 20.